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The BRAF inhibitors vemurafenib and dabrafenib can be used to
treat patients with metastatic melanomas harboring BRAFV600 muta-
tions. Initial antitumoral responses are often seen, but drug-resistant
clones with reactivation of the MEK–ERK pathway soon appear. Re-
cently, the secretome of tumor-derived extracellular vesicles (EVs)
has been ascribed important functions in cancers. To elucidate the
possible functions of EVs in BRAF-mutant melanoma, we determined
the RNA content of the EVs, including apoptotic bodies, microve-
sicles, and exosomes, released from such cancer cells after vemura-
fenib treatment. We found that vemurafenib significantly increased
the total RNA and protein content of the released EVs and caused
significant changes in the RNA profiles. RNA sequencing and quan-
titative PCR show that cells and EVs from vemurafenib-treated
cell cultures and tumor tissues harvested from cell-derived and
patient-derived xenografts harbor unique miRNAs, especially in-
creased expression of miR-211–5p. Mechanistically, the expression
of miR-211–5p as a result of BRAF inhibition was induced by in-
creased expression of MITF that regulates the TRPM1 gene resulting
in activation of the survival pathway. In addition, transfection of
miR-211 in melanoma cells reduced the sensitivity to vemurafenib
treatment, whereas miR-211–5p inhibition in a vemurafenib resistant
cell line affected the proliferation negatively. Taken together, our
results show that vemurafenib treatment induces miR-211–5p up-
regulation in melanoma cells both in vitro and in vivo, as well as in
subsets of EVs, suggesting that EVs may provide a tool to understand
malignant melanoma progression.
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Approximately half of all malignant melanoma tumors harborBRAF somatic missense mutations, and these most often
occur at amino acid residue V600 (1). Inhibition of BRAFV600
with the FDA-approved drugs vemurafenib or dabrafenib results
in rapid regression of metastatic melanoma tumors harboring
this mutation (2). Unfortunately, resistance often follows the
immediate antitumor effect of these drugs, and this resistance is
associated with reactivation of MAPK pathways or by alternative
BRAF splicing (3).
The eukaryotic genome encodes two categories of noncoding
RNAs (ncRNAs), referred to as “small ncRNAs” and “long
mRNA-like ncRNAs” (4). Small ncRNAs are 20–200 nucleotides
(nt) in length and include species such as miRNAs, piRNAs,
siRNAs, tRNAs, snRNAs, snoRNAs, vaultRNAs, and other
less well-characterized RNA species (5). The functional role of
these small RNAs, especially miRNA, siRNA, and piRNA, is
gene silencing by interaction with chromatin or by base pairing
with complementary mRNAs or DNAs (6–9). It has recently
been established that RNA molecules not only are retained
in the cytoplasm of the cells, but they can also be released into
the extracellular milieu, often in extracellular vesicles (EVs)
(10, 11). It has also been shown that extracellular vesicles
can transfer functional RNA between cells (12). In addition,
different subsets of vesicles such as apoptotic bodies, micro-
vesicles, and exosomes contain distinct RNA molecules, espe-
cially miRNA, that are unique to different exosomal subsets
(5, 13). These observations have opened a field of research
aiming to understand the vesicular contents and function under
different conditions and how they influence the function of
the vesicles.
The role of ncRNAs in different diseases, including melanoma,
has been investigated, but relatively little is known about the RNA
species present in extracellular vesicles that are derived from
melanoma cells. We hypothesized that the populations of small
RNA molecules present in subsets of extracellular vesicles change
after vemurafenib treatment, which could alter the extracellular
vesicles’ biological function. To test this hypothesis, we used next
generation sequencing and quantitative PCR (qPCR) approaches
to compare the changes in the RNA contents in extracellular
vesicles upon inhibition of BRAFV600 with vemurafenib in cul-
tured malignant melanoma cells, in cell line-derived xenografts
(CDXs), and in patient-derived xenografts (PDXs). In addition,
we also determined the mechanism behind the induced ex-
pression of miRNA upon vemurafenib treatment in malignant
melanoma cells.
Significance
The development of BRAF inhibitors is a notable clinical suc-
cess, leading to rapid initial melanoma regression. However,
response rates are tempered by a short duration of response in
a majority of patients. This study has determined the effects of
BRAF inhibition on mutant melanoma cells, as well as on the
RNA contents in their vesicular secretome. Our data show the
presence of miR-211–5p in all extracellular vesicular (EV) sub-
sets upon treatment with BRAF inhibitors, which provides a
fundamental starting point to understand the regulatory ef-
fects of molecules present in EVs, which may have implications
for disease progression in patients receiving BRAF-targeted
treatment.
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Results and Discussion
BRAF Inhibition Increases the RNA and Protein Content in Extracellular
Vesicle Isolates. Treatment of MML-1 cells with the BRAF in-
hibitor vemurafenib for 72 h resulted in a dose-related attenuation
of cell viability (Fig. 1A). A concentration of 200 nM vemurafenib
was considered optimal for further experiments, as this concen-
tration resulted in 50% viability after 72 h of treatment (Fig. 1B).
The conditioned media were harvested 72 h after the treatment,
and extracellular vesicles were isolated using differential centri-
fugation. Measuring the RNA and protein concentration among
the extracellular vesicle subsets from treated and nontreated cells
showed that the RNA and protein concentration was significantly
increased in apoptotic bodies, microvesicles, and exosomes after
treatment (Fig. 1 C and D). This increase in total RNA and
protein content shows that the release of extracellular vesicles is
caused by vemurafenib treatment in melanoma cells. The RNA/
protein ratio was not significantly altered in the microvesicles and
apoptotic bodies; however, vemurafenib treatment decreased the
RNA/protein ratio in the exosome fraction (Fig. 1E), arguing
against increased loading of RNA into extracellular vesicles.
Vesicles were then characterized using Western blot to de-
termine the presence of established extracellular vesicle protein
markers such as TSG-101 and CD81. These molecules were
enriched in the exosomes from both treated and nontreated cells
compared with the other extracellular vesicle subpopulations
(Fig. 1F). Calnexin, an endoplasmic reticulum marker, was pre-
sent in apoptotic bodies but was absent in exosomes and micro-
vesicles, confirming that the differential centrifugation separation
of apoptotic bodies from the other two extracellular vesicle sub-
types was efficient. Melan-A (also called MART-1), an antigen
on melanoma cells, was present in all vesicle subpopulations,
whereas BRAFV600E was detected only in the cells and apoptotic
bodies (upper band, Fig. 1F). β-Actin was used as the loading
control for cells, and it was also shown to be present in all ex-
tracellular vesicle subsets. This protein characterization shows
that there is no change in the presence of protein markers in the
vesicles upon vemurafenib treatment, but the treatment alters the
RNA and protein content in the extracellular vesicles derived
from melanoma cells.
Vesicles from Treated Cells Carry a Diverse Repertoire of ncRNAs.
Given that the cells release greater quantities of all extracellular
vesicle subsets after vemurafenib treatment, the RNA cargos of
all extracellular vesicle subsets were analyzed in biological du-
plicates with a bioanalyzer instrument and by small RNA deep
sequencing. The bioanalyzer showed clear peaks for the 5S
rRNA and the 18S and 28S rRNA subunits as well as tRNA in
the apoptotic bodies and microvesicles (Fig. S1). However, the
peaks for the rRNA subunits were not as prominent in the
exosomes, supporting our previous findings arguing that smaller
exosomes carry relatively little rRNA (5, 13). The total RNA and
small RNA profiles did not show a significant difference in the
extracellular vesicle subset after treatment (Fig. S1).
The small RNA deep sequencing for the nontreated samples
has previously been analyzed and published (5), and the same
raw data were now reanalyzed together with the treated samples
to determine the differences in the cells and extracellular vesicle
subsets upon vemurafenib treatment. Analysis of the small RNA
deep sequencing was focused on ncRNAs, and first an average of
the duplicates of all of the samples was calculated and then the
percentage of sequencing reads for the different RNA species
was determined. The distribution of mapped ncRNAs is shown
Fig. 1. Vemurafenib treatment increases the RNA and protein cargo in extracellular vesicle subsets. (A) Dose–response curve of vemurafenib treatment in
MML-1 cells. The relative percent cell viability was assessed with an MTT assay. (B) Cell count of MML-1 cells after 200 nM vemurafenib treatment for 72 h. The
cells were counted with a trypan blue exclusion assay. (C) RNA content in the subsets of EVs released by nontreated and treated cells, normalized per million
cells (n = 5). (D) Protein content in the subsets of extracellular vesicles released from nontreated and treated cells, normalized per million cells (n = 5). (E) RNA/
protein ratio in subsets of extracellular vesicles upon vemurafenib treatment (n = 5). (F) Western blot showing characteristics of extracellular vesicles using
exosomal markers and melanoma markers. β-Actin was used as the loading control for cells. Data are presented as ± SEM. ABs, apoptotic bodies; EXO,
exosomes; and MVs, microvesicles. *P < 0.05, **P < 0.01.
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in Fig. 2A. We identified the presence of yRNA, snRNA, tRNA,
snoRNA, rRNA, lincRNA, piwiRNA, miRNA, and mRNA.
Exosomes contained a higher proportion of miRNA compared
with apoptotic bodies and microvesicles (indicated in red, Fig.
2A). Although all vesicle subsets contained a lower proportion of
snoRNA than the cells (indicated in green, Fig. 2A), the exo-
somes carried a unique set of snoRNAs, clustering separately
from cells, microvesicles, and apoptotic bodies (Fig. 2B). A few
studies have shown the presence of tRNA in exosomes from
neuronal cells (14), plasma exosomes (15), and immune cells
(16), but little is known about the presence of tRNA in apoptotic
bodies and microvesicles. In this study, a larger proportion of
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Fig. 2. Sequencing analysis of small ncRNAs in subsets of extracellular vesicles from nontreated and treated cells. (A) The data show the percentage and
distribution of sequencing reads mapping to ncRNAs in cells and extracellular vesicles. (B) Hierarchical clustering of significant snoRNAs in cells and extra-
cellular vesicles. (C) tRNA distribution of mapping to respective tRNA isoacceptors. The numbers indicate the percentage of tRNA in cells and extracellular
vesicles. (See Fig. 1 legend for repeated abbreviations.) +, treated; −, nontreated.
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the reads were mapped as tRNA in the extracellular vesicles
compared with cells (indicated in black, Fig. 2A). The largest
percentage of tRNA was found in microvesicles, which supports
the small RNA profiles from the bioanalyzer where microvesicles
had the most prominent tRNA peak (Fig. S1B). Glutamate and
glycine tRNAs were enriched in vesicles compared with cells
(Fig. 2C). In addition, valine tRNA was enriched in exosomes
compared with other EV subpopulations and cells. This shows
that extracellular vesicles encapsulate most tRNAs that are
processed in the cytoplasm of the cells that are producing ex-
tracellular vesicles. On the other hand, aspartic acid, proline,
and alanine tRNAs were enriched in cells but were barely
present in the different subsets of extracellular vesicles. Our
data suggest that other extracellular vesicle subsets besides
exosomes also have the capacity to carry tRNA. Together, these
results show that all subsets of vesicles released by mela-
noma cells carry several different ncRNA species and that the
relative proportions of these ncRNAs are not altered upon
BRAF inhibition.
BRAF Inhibition Affects miRNA Loading in the Extracellular Vesicle
Subsets. Although the relative portion of each ncRNA species
did not change upon vemurafenib treatment, the expression of
individual RNA molecules could be altered. Therefore, we de-
termined the effect of BRAF inhibition on the miRNA contents
in the different subsets of extracellular vesicles. A Venn diagram
showed that most of the miRNAs were common in treated and
nontreated cells and in all extracellular vesicle subsets (Fig. 3A).
However, this analysis also showed several unique miRNAs,
suggesting that vemurafenib treatment alters the miRNA con-
tent in cells and in the different extracellular vesicle subgroups
(Fig. 3A). Hierarchical clustering of the 130 miRNAs that were
abundantly present in all samples further demonstrated that
exosomes in both treated and nontreated samples contain unique
sets of miRNA compared with cells and the other subsets of
vesicles (Fig. 3B, cluster 2), confirming our previous observation
(5). Interestingly, some miRNAs, such as miR-211–5p, miR-132–
3p, and miR-10b–5p, were expressed at higher levels in cells and
exosomes from treated cells compared with cells and exosomes
from nontreated cells (Fig. 3B, cluster 1). Of the 130 miRNA
abundantly present in all samples, 7 were significantly differen-
tially expressed in cells upon treatment (Fig. S2A). For the ex-
tracellular vesicle subsets, one miRNA had significantly altered
expression in apoptotic bodies, one had significantly altered ex-
pression in microvesicles, and three had significantly altered
expression in exosomes (Fig. S2 C, E, and G). Using qPCR, we
validated several of these significantly altered miRNAs. Notably,
we could confirm that miR-211–5p was significantly up-regulated
in treated cells as well as in their extracellular vesicles (Fig. 3C).
Deep sequencing also suggested that miR-34a–5p was signifi-
cantly up-regulated in cells upon treatment, which was validated
with qPCR (Fig. S2 A and B). The down-regulation of miR-15b–
5p in cells, miR-4443 in apoptotic bodies, miR-218–5p in
microvesicles, and miR-9–5p in exosomes upon treatment was
not supported by qPCR, but these all showed a trend of being
down-regulated (Fig. S2 A–H). The deep sequencing showed no
significant difference in miR-16–5p and miR-103a–3p in cells
and exosomes, which was confirmed with the qPCR (Fig. 3B and
Fig. S2 B andG). Overall, these results validate the findings from
the deep sequencing.
It was interesting to note that the sequencing data could only
detect the up-regulation of miR-211–5p in MML-1 cells (Fig.
S2A), whereas the qPCR could also detect this increase in ex-
pression in all extracellular vesicle subsets (Fig. 3C). The in-
crease of miR-211–5p in cells as well as in all extracellular vesicle
subsets was also observed upon treatment in A375 cells, another
cell line harboring the BRAFV600E mutation (Fig. S2I). To con-
firm that the increased miR-211–5p expression was specific for
and limited to BRAF inhibition and not induced by cellular
toxicity and apoptosis, another BRAFV600E inhibitor, dabrafenib,
was used. The concentration of dabrafenib was determined by
first treating MML-1 cells with several doses (0–3,000 nM), and a
concentration of 100 nM was then selected for further experi-
ments, as this concentration resulted in 50% viability (Fig. S3A).
For cytotoxicity experiments, MML-1 cells were exposed to dif-
ferent exposure of UV light and 80 J/m2 was used as optimal
exposure for further experiments, as this concentration resulted
in 50% viability (Fig. S3B). Treatment of MML-1 cells with the
BRAF inhibitors dabrafenib (100 nM) or vemurafenib (200 nM)
or with UV light or combinations thereof did not alter the cel-
lular RNA profiles [RNA integrity number (RIN) value for each
profile = 10; Fig. S3C]. Treatment of MML-1 cells with the
BRAF inhibitor dabrafenib (100 nM) supported our findings
from vemurafenib treatment, as it also induced an increased
miR-211–5p expression in cells and extracellular vesicles re-
leased by the treated cells (Fig. S3 D–G). On the other hand,
there was no significant difference in the miR-211–5p expression
in cells and extracellular vesicles when MML-1 cells were UV
treated (80 J/m2) compared with the nontreated cells and vesi-
cles, indicating that the expression of miR-211–5p is specific and
limited to BRAFV600E inhibition and not induced by cellular
toxicity and cell death (Fig. S3 D–G). Furthermore, the cells
surviving the UV treatment could still increase the miR-211–5p
expression as well as their secreted EVs miR-211–5p expression
upon vemurafenib and dabrafenib treatment (Fig. S3 D–G). In
addition, we also tested the effect of the pan-caspase inhibitor,
qVD-OPH, which is known to inhibit apoptosis and prevents cell
death that has been induced by metformin in melanoma cells (17).
Interestingly, vemurafenib treatment showed a significant increase
in miR-211–5p expression compared with nontreated cells also
when combined with qVD-OPH treatment (Fig. S3H). Again this
increase indicates that the expression of miR-211–5p is induced by
the BRAF inhibition and is not induced by apoptosis as the miR-
211–5p expression is stable also when apoptosis is inhibited in
vemurafenib-treated cells. qVD-OPH treatment alone did not af-
fect the miR-211–5p expression. Similarly, miR-211–5p was also
significantly enriched in the extracellular vesicles derived from
vemurafenib and qVD-OPH cotreated cells (Fig. S3 I–K), sug-
gesting that the loading of miR-211–5p cargo in the extracellular
vesicle subset is dependent on BRAF inhibition and independent
of apoptosis.
Together, these results strongly suggest that miR-211–5p is up-
regulated upon BRAFV600E inhibition in BRAFV600E melanoma
cells and that miR-211–5p is loaded into all subsets of extracel-
lular vesicles released by the treated cells.
miR-211–5p Is Up-Regulated in Extracellular Vesicles from CDXs and
PDXs. To confirm the in vitro validation of the miRNA expres-
sion, we transplanted MML-1 cells into the flanks of 10 NOG
(nonobese severe combined immune deficient interleukin-2
receptor chain γ knockout) mice. When the s.c. tumors had
reached a volume of around 200 mm3, the mice were randomized
into two groups, one receiving food containing vemurafenib and
the other receiving standard chow. Three days after the start of
vemurafenib treatment, a significant reduction in tumor size had
occurred compared with the vehicle control (Fig. 4A). Upon
killing the mice, the tumors were harvested and showed a sig-
nificant reduction in tumor weight (Fig. 4B). All tumors were
processed into single-cell suspensions and expanded in vitro as a
monolayer. The extracellular vesicles released from these cul-
tures over the course of 24 h were used for RNA isolation and
subsequent qPCR analyses, which showed significant up-
regulation of miR-211–5p in cells and in all extracellular vesi-
cle subsets isolated from the vemurafenib-treated tumors
(Fig. 4C).
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Fig. 3. Vemurafenib alters the miRNA expression in subsets of extracellular vesicles. (A) Venn diagrams showing the average of reads of unique miRNAs in
nontreated (NT) and treated (T) cells and extracellular vesicles using small RNA sequencing. (B) Hierarchical clustering of miRNA in cells and exosomes upon
vemurafenib treatment. The clustering shows the differential regulation of miRNA: red, up-regulated and blue, down-regulated. (C) Validation of
miR-211–5p by qPCR in cells and extracellular vesicles supported the results of the small RNA sequencing. The fold change in expression between treated and
nontreated cells was normalized with respect to the C. elegans external spike-in miR-39–3p (n = 3). Data are presented as ± SEM. *P < 0.05. (See Figs. 1 and 2
legends for repeated abbreviations.)
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To make our work more clinically significant, we established
PDXs by transplanting cells from a BRAFV600K mutated lymph
node metastasis that had been surgically removed from a patient
with stage IIIC malignant melanoma (18) into the flanks of 10
NOG mice. Tumors in this mouse model also responded to
vemurafenib treatment (Fig. 4 D and E), and miR-211–5p was
similarly up-regulated in cells and extracellular vesicles (Fig. 4F).
We also observed differential expression of the other signifi-
cantly altered miRNAs from the deep sequencing analysis in
cells and extracellular vesicle subsets from the CDXs and PDXs,
although the validation was not evident in all settings (Fig. S4 A
and B). The levels of miR-211–5p in serum (∼200 μL) of mice
bearing tumors and being treated with vemurafenib or dabrafe-
nib, was not quantifiable with qPCR, and thus larger plasma or
serum volumes may be required for its detection. Indeed, it is
known from analysis of liver perfusates of liver metastatic uveal
melanoma that melanoma-associated miRNAs can be detected
in circulating exosomes when larger blood volumes are analyzed
(19). Future clinical studies could determine whether miR-211–
5p can be detected in clinical samples of melanoma patients
undergoing BRAF-targeted therapy.
Together the CDXs and PDXs models demonstrate that miR-
211–5p is not only up-regulated upon vemurafenib treatment in
our in vitro model but also in tumor cells and their extracellular
vesicle subsets in vivo. Importantly, the up-regulation of miR-
211–5p was increased severalfold in the PDXs, implying that the
increase in miR-211–5p in tumor cells as well as secreted in
extracellular vesicles is clinically relevant.
Fig. 4. BRAF inhibition up-regulates miR-211–5p expression in MML-1 CDXs and PDXs. MML-1 cells (with the BRAFV600E mutation) and patient cells (with the
BRAFV600K mutation) were transplanted s.c. into the mice, and tumors were allowed to grow until they attained a size of 150–200 mm3. The mice were then
divided into vehicle and treatment groups, and the tumors were harvested at 3 d posttreatment. (A and D) Tumor size as measured with calipers. The
treatment was initialized with PBS and vemurafenib in the food when the tumor size reached 150–200 mm3. (B and E) Weight of tumors harvested and
measured 3 d after the treatment. (C and F) Validation of miR-211–5p in cells and extracellular vesicles derived from tumors. The fold change between the
nontreated and treated cells and extracellular vesicles was normalized with respect to C. elegans external spike-in miR-39–3p (n = 5 in each group). Data are
presented as ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (See Figs. 1 and 2 legends for repeated abbreviations.) Vem, vemurafenib.
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BRAF Inhibition Up-Regulates miR-211–5p Expression Through Master
Regulator MITF. To determine the mechanism behind the increase
in miR-211–5p expression after vemurafenib treatment, MML-1
whole-cell lysates from treated and nontreated cells were used to
evaluate the genes involved in the MITF pathways in melanoma.
It is well known that inhibition of BRAFV600E leads to down-
regulation of pERK1/2, which consequently increases the
levels of MITF in the nuclear component (20). This was con-
firmed by Western blot that showed a down-regulation of
pERK1/2 and an increase in MITF (Fig. 5A). The increase in
MITF was also confirmed with qPCR (Fig. 5B). Furthermore, it
has been shown that MITF regulates TRPM1 gene expression as
well as the expression of miR-211–5p, as it resides in the sixth
intronic region of TRPM1 (21, 22). A significant up-regulation of
TRPM1 was confirmed by qPCR (Fig. 5B), which may explain
the induced expression of miR-211–5p in the melanoma cells as
shown by qPCR in Fig. 3C. Further, high levels of MITF and
miR-211 have also been shown to regulate the genes that are
involved in the differentiation of melanoma cells (23, 24). This
regulation of differentiation was also confirmed by qPCR, and
the vemurafenib treatment induced significant changes in the
expression of genes involved in differentiation, such as TYR and
TRP1 (Fig. 5B). Additionally, it has been shown that the anti-
apoptotic protein Bcl-2 is a direct target of MITF and that
modulation of Bcl-2 regulates Melan-A (25). We therefore also
evaluated the expression of Bcl-2 and Melan-A with Western
blot and qPCR. Bcl-2 and Melan-A expression was increased
after vemurafenib treatment, which suggests that the high MITF
levels directly regulate Bcl-2 and thus activate the survival
pathway (Fig. 5 A and B). It has previously been shown that this
pathway also leads to tolerance toward vemurafenib treatment in
melanoma cells by inducing the expression of miR-211–5p in
response to Melan-A expression (24). Together these results
suggest that inhibition of BRAF by vemurafenib regulates the
pERK 1/2 and MITF pathway leading to up-regulation of
TRPM1 thus inducing miR-211–5p expression. The activation of
this pathway also induces survival pathways, which suggests that
tolerance to vemurafenib is induced in the melanoma cells.
Stable Expression of miR-211–5p Reduces Sensitivity to BRAF Inhibition.
To determine whether stable expression of miR-211 in low-
expressing miR-211–5p melanoma cells (26) could reduce the
sensitivity toward vemurafenib treatment, MML-1 cells were
transfected with miR-211 and scrambled lentiviral vectors and the
cells were selected with puromycin, and 100% of the cells were
positive for mCherry, which confirmed that only transfected cells
were used for downstream analysis. The morphology of the cells
was not affected by transfection with miR-211 compared with
transfection with a scrambled vector (Fig. 6A). As determined by
qPCR analysis, miR-211–5p was overexpressed in miR-211–
transfected cells compared with the scrambled cells (Fig. 6B).
Furthermore, miR-211–transfected cells showed enhanced pro-
liferation as determined by cell counts after 72 h (Fig. 6C). To
determine the mechanism of reduced sensitivity, the transfected
cells were treated with vemurafenib and assayed for miR-211–5p
expression by qPCR. Indeed, vemurafenib treatment of both
scrambled and miR-211–transfected cells increased miR-211–5p
expression compared with the nontreated cells (Fig. 6D). In-
terestingly, we found a 100-fold increase in miR-211–5p expres-
sion in vemurafenib-treated miR-211–5p–transfected cells (Fig.
6D), suggesting that vemurafenib regulates either the U6 pro-
moter driving the exogenous expression or the processing of miR-
211–5p. Furthermore, the MTT assay showed that treatment with
vemurafenib reduced cell proliferation at 72 h in cells transfected
with scrambled RNA but not in cells transfected with intact miR-
211 (Fig. 6E), suggesting that miR-211–5p up-regulation upon
vemurafenib treatment allows these cells to survive and grow into
a population of cells that have reduced sensitivity to vemurafenib.
To evaluate the expression of miR-211–5p in resistant cells,
MML-1 cells were grown in the presence of increasing doses of
vemurafenib (0.2 μM–10 μM) over a period of 10 months to
generate a vemurafenib-resistant cell line (Fig. S5 A–C). Notably,
the miR-211–5p expression was 16-fold significantly higher in re-
sistant cells compared with the sensitive cells (Fig. 6F). Further-
more, inhibition of miR-211–5p in these cells at 24 h decreased
cellular proliferation, suggesting the involvement of miR-211–5p
in driving the reduced sensitivity to BRAFV600E inhibition in
melanoma (Fig. 6G). Overall, these results suggest that miR-211–5p
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Fig. 5. BRAF inhibition up-regulates miR-211–5p expression by regulating the survival pathways. (A) Immunoblotting of genes involved in survival pathways.
The images are representative of three individual experiments. GAPDH was used as the loading control for the cells. (B) Fold change expression of differ-
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can reduce the sensitivity to vemurafenib treatment in melanoma
cells by regulating cellular proliferation.
In this study, we found that inhibition of BRAFV600E with
vemurafenib (PLX4032) is associated with increased secretion of
extracellular vesicles from melanoma cells. We also observed
increased secretion of miRNAs, specifically miR-211–5p, which
can be significant for melanoma progression. The fact that
released extracellular vesicles shuttle significant amounts of func-
tional proteins and biologically active RNA cargo between cells
suggests that such communication is likely to be important for
melanoma progression. We also discovered that miR-211–5p is
induced upon BRAFV600E inhibition in melanoma cells and in
certain subsets of vesicles, and that overexpression of miR-211–
5p reduces sensitivity to BRAFV600E inhibition in the melanoma
cells. Our results indicate that treatment of melanoma cells with
an oncogene inhibitor causes significant changes in the RNA
cargo in the melanoma cells and in the subsets of extracellular
vesicles that they excrete, and such communication might lead
to altered gene expression within the population of melanoma
cells that reduces sensitivity to the inhibitor and decreases the
inhibitor’s efficiency.
We show here that miR-211–5p expression is induced upon
BRAFV600E inhibition due to the up-regulation of MITF, and
this increase in miR-211–5p expression promotes survival in
parent melanoma cells despite a reduction in ERK1/2 activity.
This has also been discussed in a study that demonstrated that
overexpression of MITF in melanoma cells promotes survival
and proliferation (27). Another recent study also suggests that
melanosomes, but not exosomes, derived from melanoma cells,
transport miR-211 to cancer-associated fibroblasts, and trans-
porting of miR-211 leads to increased proliferation, migration,
and proinflammatory gene expression by the fibroblasts (28).
Our study adds to the above finding by showing that the ex-
pression of miR-211–5p is substantially up-regulated upon
vemurafenib treatment in the melanoma cells and in subsets of
extracellular vesicles, including exosomes. Our finding of miR-
211–5p in subsets of extracellular vesicles still needs to be
functionally assessed to determine its possible role in the regu-
lation of cancer progression.
Additionally, miR-211 has been shown to function as a met-
abolic switch in melanoma cells by targeting the hypoxia in-
ducible factor 1α (HIF-1α), and loss of miR-211–5p is expected
to promote cancer hallmarks in human melanomas (29). It was
further suggested that miR-211 acts as a molecular switch that is
usually turned off in many melanomas, and figuring out how and
when to turn this switch on might provide insights into better
treatment for melanomas (29, 30). Our finding that miR-211–5p
is increased in cells upon vemurafenib treatment could support
the development of more targeted therapies against melanoma
cells in which miR-211 is up-regulated.
Fig. 6. Stable expression of miR-211–5p reduces sensitivity to vemurafenib. (A) Representative images of the MML-1 cells transfected with scrambled (scr) or
miR-211 vectors. (B) The relative expression of miR-211–5p in MML-1 cells transfected with the miR-211–expressing lentiviral vector compared with MML-1
cells transfected with the scrambled gene-expressing vector. C. Elegans miR-39–3p was used as the external spike-in control to normalize the expression.
(C) Cell counting shows that miR-211–5p–transfected cells proliferate more than the cells transfected with the scrambled gene. Cells were counted with the
trypan blue exclusion assay. (D) Fold change in miR-211–5p expression with respect to C. elegans miR-39–3p between the scrambled and miR-211–transfected
cells upon vemurafenib treatment. (E) Relative percent cell proliferation measured by MTT assay. The MTT assay was performed after 72 h of vemurafenib
treatment. (F) Fold change regulation of miR-211–5p in MML-1R cells compared with the sensitive parental MML-1 cells. The fold change was normalized to
the external spiked-in C. elegansmiR-39–3p. (G) MML-1R cells were plated onto a 96 well plate at a density of 10,000 cells per well. Cells were transfected with
control oligos or miR-211–5p inhibitors and the cellular proliferation was assessed by MTT after 24 h by using absorbance spectrum at 570 nm. All experiments
were performed three times independently. Data are presented as ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (See Fig. 5 legend for repeated
abbreviations.) MML-1R, MML-1 resistant cells; MML-1S, MML-1 sensitive cells.
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The emergence of BRAF inhibitors is a remarkable clinical
success (31). However, the impressive response rates have been
tempered by a short duration of response in a majority of pa-
tients (31). Until now, no studies have determined the effects of
vemurafenib treatment on BRAF mutant melanoma cells or on
the molecular contents of their extracellular vesicles. Our data
provide a crucial starting point to understand the effects of
BRAF inhibition on microRNA expression in the treated cells
and their vesicular secretome, which can have implications for
the progression and metastasis of malignant melanoma un-
dergoing such treatment.
Materials and Methods
Cell Culture and Extracellular Vesicle Isolation. The melanoma cell lines MML-1
and A375, both having a BRAFV600E mutation, were cultured as described
previously (5). Vemurafenib (PLX4032) and dabrafenib were dissolved in
DMSO as recommended by the manufacturer instructions (Selleckchem).
MML-1 cells were treated with increasing concentrations of vemurafenib (0–
1,000 nM) or dabrafenib (0–3,000 nM) to determine the optimal dose for the
treatments. Cells were trypsinized, and cell viability and cell counts were
obtained by trypan blue exclusion. For vesicle isolation, cells were first pel-
leted by centrifugation at 300 × g, and the conditioned medium was then
spun at 2,000 × g for 20 min to pellet apoptotic bodies and then at 16,500 × g
for 20 min to pellet microvesicles. Finally, after filtration through a 0.22-μm
filter, the medium was centrifuged at 120,000 × g for 70 min to pellet
exosomes. All of the vesicle-containing pellets were resuspended in PBS or
lysed in RNA lysis buffer for further analysis.
Mouse Experiments. All animal experiments were performed in accordance
with European Union directive 2010/63 (Regional Animal Ethics Com-
mittee of Gothenburg approval 287/289–12 and 36–2014). Establishment
of PDXs was performed as previously described (18). For the establish-
ment of the CDXs, MML-1 cells were suspended in culture media and
mixed 1:1 with Matrigel (BD Bioscience), and 2 × 105 cells were trans-
planted s.c. into the flank of NOD-SCID IL2Rcnull (NOG) mice. Growth of
the xenografts was followed by measuring with a caliper, and when the
xenografts had increased two measurements in a row, the mice were
randomized into two treatment groups, receiving either normal food or
fodder containing Zelboraf (vemurafenib, Roche) (240 mg/kg/d; Research
Diets Inc.). After 3 d of treatment, tumors were harvested and weighed. In
addition, the tumors were dispersed into fine pieces using a tissue chopper, and
collagenase D (2 mg/mL) and DNase (400 units/mL) were added and the tumor
suspension was incubated for 30 min at 37 °C. The medium with the tumor
cells was filtered through a 70-μm filter, and fresh medium containing 10%
exosome-depleted FBS and penicillin–streptomycin (10 units/mL) was added
to the required volume and cultured for 24 h. The isolation of extracellular
vesicles was carried out as described in Cell Culture and Extracellular Vesicles
Isolation.
Generation of Vemurafenib-Resistant MML-1 Cells. To generate vemurafenib-
resistant cells, MML-1 cells were cultured in RPMI-1640 growth medium
without antibiotics. The concentration of vemurafenib was gradually in-
creased from 0.2 μM to 10 μM for ∼10 mo, which resulted in a resistant cell
line called MML-1R.
Flow Cytometry. MML-1 (parent) and MML-1R cells were plated in 24-well
plates at a cell density of 75,000 cells per well. The cells were allowed to adhere
overnight and were then treated with vemurafenib at a concentration of 5 μM
for 24 h. The cells were then trypsinized, washed with PBS, and labeled with
7-AAD in modified Vindelov’s solution (20 mM Tris pH 8.0, 100 mM NaCl,
1 μg/mL 7-AAD, 20 μg/mL RNase, and 0.1% Nonidet P-40) for 30 min at 37 °C.
DNA content was analyzed on a BD Accuri C6 (Becton-Dickinson) using the
FL3 channel in logarithmic scale for sub-G1 measurements (apoptosis).
Immunoblotting. The lysis of extracellular vesicles and protein estimation was
carried out using RIPA buffer and the BCA Protein Assay Kit (Pierce, Thermo
Scientific) as described previously (5, 32). The primary antibodies used were
Melan-A (1:1,000 dilution), Calnexin (1:1,000), CD81 (1:1,000), Bcl-2 (1:1,000),
GAPDH (1:1,000), and BRAF (1:1,000) from Santa Cruz Biotechnology; TSG-
101 (1:1,000; clone 4A10) from Abcam; c-Myc (1:1,000), β-actin (1:1,000),
pERK1/2 (1:1,000), total ERK1/2 (1:1,000), and MITF (1:1,000) from Cell Sig-
naling Technology; and BRAFV600E (1:1,000) from Spring Biosciences. The
primary antibodies were incubated with the blot overnight at 4 °C. The
membranes were washed three times in Tris buffer saline with 0.1% Tween
20 (TBST) and incubated with secondary antibodies for 1 h at room tem-
perature. The secondary antibodies were ECL anti-rabbit IgG horseradish
peroxidase-linked F(ab′)2 fragment (donkey anti-rabbit) and ECL anti-
mouse IgG horseradish peroxidase-linked F(ab′)2 fragment (sheep anti-
mouse) (GE Healthcare). The membranes were washed again three times
for 5 min in TBST buffer and detected and analyzed with ECL Prime
Western Blotting Detection (GE Healthcare) and a VersaDoc 4000 MP (Bio-
Rad Laboratories).
Small RNA Sequencing and Analysis. The RNA isolation and sequencing
analysis of nontreated MML-1 cells and subsets of extracellular vesicles was
performed as previously described (5). The isolation and analysis of treated
cells and extracellular vesicles was performed using the same methods as
nontreated cells and extracellular vesicles. Cellular RNAs with a RNA in-
tegrity number above 8 as measured by the Agilent Bioanalyzer RNA 6000
Nano assay were used for small RNA deep sequencing. Following RNA ex-
traction, libraries were constructed from 50 ng of RNA using the Ion Total
RNA-Seq Kit V2 (Life Technologies) and ligated to adapters containing a
unique index barcode (Ion Xpress RNA-Seq Barcode 1–16 Kit; Life Technol-
ogies) according to the manufacturer’s protocol. The yields and size distri-
butions of the small RNA libraries were assessed using the Agilent 2100
Bioanalyzer instrument with the high-sensitivity DNA chip (Agilent Tech-
nologies). Equally pooled libraries were prepared for deep sequencing using
the Ion OneTouch System (Life Technologies) and sequenced on the Ion
Torrent PGM using Ion 318 V2 chips (Life Technologies) and the Ion PGM
200 V2 Sequencing Kit (Life Technologies). Preprocessing of reads and the
removal of adapters and barcodes were performed using Torrent Suite
(v.3.4.1). Sequences were analyzed for quality control (FASTQC) and aligned
to the human genome (HG19) using Torrent Suite, and files were transferred
to Partek Genomic Suite and Flow (Partek, Inc.) for mapping against miRBase
V.21 and Ensembl Release 75 to identify miRNA, ncRNA, and coding RNA
species. Reads were normalized to reads per million. miRNAs identified with
at least 10 reads were used for further analysis in the Partek Genomic suite,
which included statistical analysis and hierarchical clustering.
MTT Cell Proliferation Assay. MML-1 cells were plated on a 96-well plate to
determine the dose–response after 72 h of vemurafenib or dabrafenib
treatment. A total of 5,000 cells were plated in each well, and MTT was
added at the end point to determine the cell viability.
Furthermore, stably expressing miR-211 MML-1 cells and MML-1R cells
were also plated in 96-well plates at a seeding density of 5,000 and
10,000 cells per well, respectively. Additionally, the MML-1R cells were
transfected with miR-211–5p inhibitors (Exiqon) or control miRNA oligos to
determine the physiological relevance of cells by determining the cellular
proliferation. Vemurafenib was used to treat both the stably expressing
miR-211 MML-1 cells and MML-1R cells, and MTT was added at the end
point to determine the cell proliferation.
Validation of miRNAs. Separate miRNA primer assays (Exiqon) were performed
on RNA prepared fromMML-1, A375 cells (the same batch of cells used for the
isolation of extracellular vesicles as previously published) (5), CDXs, PDXs, and
extracellular vesicles. Before cDNA synthesis, all of the samples were treated
with DNase (Ambion), deactivated with DNase inactivation buffer, and the
RNA was extracted. For cDNA synthesis and qPCR, the protocol was followed
as described earlier (5). Caenorhabditis elegans miR-39–3p was used as the
normalizing control as an external spike in, and UniSp6 was used as an internal
spike-in control. The plate was run on a Bio-Rad CFX96 (Bio-Rad Laboratories)
real-time detection system for 40 cycles following the manufacturer’s protocol.
Data were analyzed according to the fold-change difference between the
treated and nontreated groups using the ΔΔCt method.
Establishment of a Stable miR-211 Expressing Cell Line. MML-1 cells were
transfected for the establishment of a stablemiR-211expressing cell line.MML-1
cells were seeded in six-well dishes and transfected with the modified
PLKO.1 vectors using Lipofectamine 2000 (Invitrogen). PLKO-mcherry-luc-puro-
shSCR and PLKO-mcherry-luc-puro-miR-211–5p (Addgene plasmids 29780 and
29784, respectively) were a kind gift from Carl Novina, Department of Der-
matology, Massachusetts General Hospital, Harvard Medical School, Boston
(33). Two days posttransfection, the cells were grown with 1 μg/mL of puro-
mycin (Invitrogen). After 4–6 wk of selection, the cells were used in
functional experiments.
Statistical Analysis. To determine the statistical significance of the RNA and
protein content, a two-tailed Student’s paired t test was used to calculate
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P values. For in vitro qPCR analysis, a paired t test and one-way ANOVA was
used, and for in vivo qPCR analysis, an unpaired Mann–Whitney u test was
performed. All of the analyses were performed using GraphPad Prism 7.0.
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